Literature DB >> 21330827

Survivin and telomerase expression in the uterine cervix of women with human papillomavirus-induced lesions.

Lyliana Coutinho Resende Barbosa1, Ismael Dale Cotrim Guerreiro da Silva, José Carlos Corrêa, Julisa Chamorro Lascasas Ribalta.   

Abstract

INTRODUCTION: Infection by human papillomavirus is the most important risk factor in the pathogenesis of uterine cervical cancer. The aims of this study were to evaluate the expression of survivin protein and telomerase enzyme in samples of uterine cervix from women with human papillomavirus-induced lesions and to determine the relationship between survivin and telomerase expression and the different grades of cervical squamous intraepithelial neoplasia and invasive cervical carcinoma.
METHODS: Biopsy samples from the uterine cervix of 105 women aged 18 to 80 years were analyzed. The patients were divided into 5 groups: WN group, 20 patients without neoplasia; CIN-1 group, 24 patients with grade 1 cervical intraepithelial neoplasia (CIN), grade 1; CIN-2 group, 20 patients with CIN grade 2; CIN-3 group, 24 patients with CIN, grade 3; and ICC group, 17 patients with invasive cervical carcinoma. Human papillomavirus detection, telomerase activity, and survivin expression were assessed using polymerase chain reaction (PCR), real-time PCR (RT-PCR), and immunochemistry, respectively.
RESULTS: There was a significant increase in the expression of telomerase and survivin associated with the severity of the lesion.
CONCLUSIONS: The results suggest that mechanisms that promote both cell proliferation (telomerase activity) and cell survival (survivin expression) are active in cervical cancer and its precursor lesions. There was a negative correlation between survivin expression and the number of PCR cycles necessary to detect telomerase activity in the total sample, achieving statistical significance in patients in the CIN-3 group.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21330827     DOI: 10.1097/IGC.0b013e318203d42b

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  7 in total

1.  Clinicopathological significance of survivin expression in patients with cervical cancer: A systematic meta-analysis.

Authors:  Yibing Fan; Juan Chen
Journal:  Bioengineered       Date:  2017-01-04       Impact factor: 3.269

2.  mRNA biomarker detection in liquid-based cytology: a new approach in the prevention of cervical cancer.

Authors:  Marta Del Pino; Cecilia Svanholm-Barrie; Aureli Torné; Lorena Marimon; Jina Gaber; Amaia Sagasta; David H Persing; Jaume Ordi
Journal:  Mod Pathol       Date:  2014-09-05       Impact factor: 7.842

3.  The association of apoptotic protein expressions sensitive to apoptosis gene, p73 and p53 with the prognosis of cervical carcinoma.

Authors:  Pinar Mega Tiber; Latife Baloglu; Sevgi Ozden; Zerrin Ozgen; Hazan Ozyurt; Makbule Eren; Oya Orun
Journal:  Onco Targets Ther       Date:  2014-11-26       Impact factor: 4.147

Review 4.  Telomerase Inhibitors from Natural Products and Their Anticancer Potential.

Authors:  Kumar Ganesan; Baojun Xu
Journal:  Int J Mol Sci       Date:  2017-12-21       Impact factor: 5.923

Review 5.  Survivin, a molecular target for therapeutic interventions in squamous cell carcinoma.

Authors:  Zakir Khan; Abdul Arif Khan; Hariom Yadav; Godavarthi B K S Prasad; Prakash Singh Bisen
Journal:  Cell Mol Biol Lett       Date:  2017-04-05       Impact factor: 5.787

6.  Telomere length in cervical exfoliated cells, interaction with HPV genotype, and cervical cancer occurrence among high-risk HPV-positive women.

Authors:  Xiaojun Chen; Sun Wei; Hongxia Ma; Guangfu Jin; Zhibin Hu; Han Suping; Dake Li; Dong Hang; Xiaohua Wu; Ni Li
Journal:  Cancer Med       Date:  2019-06-26       Impact factor: 4.452

Review 7.  Telomeres and Telomerase During Human Papillomavirus-Induced Carcinogenesis.

Authors:  Anna Pańczyszyn; Ewa Boniewska-Bernacka; Grzegorz Głąb
Journal:  Mol Diagn Ther       Date:  2018-08       Impact factor: 4.074

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.